Apogee Therapeutics, Inc.
APGE
Rank in Stocks
#2358
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Share Price
$135.07
Last synced: 2026-09-04
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
141.76%
Country
US
Trade Apogee Therapeutics, Inc. (APGE)
Category
Healthcare
Stock price history for Apogee Therapeutics, Inc. (APGE)
Highest end of day price: $135.07 on 2026-09-01
Lowest end of day price: $20.79 on 2023-07-01
Lowest end of day price: $20.79 on 2023-07-01
Stock price history of Apogee Therapeutics, Inc. from 2023 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 17.27% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $136.67 | -4.47% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
